On March 11, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported it will present new study data regarding the direct drug application of its product candidate, PH-762, at the AACR (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Phio Pharmaceuticals, MAR 11, 2021, View Source [SID1234576511]). The AACR (Free AACR Whitepaper) 2021 meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Title:
Intratumoral INTASYL self-delivering RNAi targeting PD-1 provides in vivo tumor control and mechanistic modulation of tumor microenvironment analogous to that of systemic anti-PD-1 antibody
Authors:
Benjamin Cuiffo, et al.
Session Title:
Immunomodulatory Agents and Interventions
Abstract Number:
1739
The poster presentation will be made available on the "Investors – Events and Presentations" section of the Company’s website.